Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Palvella Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was 270.5%. For fiscal 2023 it was -27.7%, against -167.8% the year before. The highest annual figure on record is 4.5% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -27.7% | +140.1 |
| FY2022 | Dec 31, 2022 | -167.8% | −2.9 |
| FY2021 | Dec 31, 2021 | -165.0% | −49.3 |
| FY2020 | Dec 31, 2020 | -115.7% | −57.0 |
| FY2019 | Dec 31, 2019 | -58.7% | +47.3 |
| FY2018 | Dec 31, 2018 | -105.9% | −48.2 |
| FY2017 | Dec 31, 2017 | -57.7% | +332.6 |
| FY2016 | Dec 31, 2016 | -390.3% | +76.3 |
| FY2015 | Dec 31, 2015 | -466.6% | −332.5 |
| FY2014 | Dec 31, 2014 | -134.2% | −138.6 |
| FY2013 | Dec 31, 2013 | 4.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | -3318.9% | −2517.7 |
| Q4 FY2023 | Dec 31, 2023 | 1030.5% | +1227.5 |
| Q3 FY2023 | Sep 30, 2023 | -60.5% | +166.1 |
| Q2 FY2023 | Jun 30, 2023 | 10.3% | +343.7 |
| Q1 FY2023 | Mar 31, 2023 | -801.2% | −733.3 |
| Q4 FY2022 | Dec 31, 2022 | -197.0% | −66.8 |
| Q3 FY2022 | Sep 30, 2022 | -226.6% | +242.0 |
| Q2 FY2022 | Jun 30, 2022 | -333.4% | +176.8 |
| Q1 FY2022 | Mar 31, 2022 | -67.9% | −35.5 |
| Q4 FY2021 | Dec 31, 2021 | -130.3% | +530.9 |
| Q3 FY2021 | Sep 30, 2021 | -468.6% | −26.3 |
| Q2 FY2021 | Jun 30, 2021 | -510.2% | −468.8 |
| Q1 FY2021 | Mar 31, 2021 | -32.4% | −3.3 |
| Q4 FY2020 | Dec 31, 2020 | -661.2% | −653.5 |
| Q3 FY2020 | Sep 30, 2020 | -442.3% | −423.0 |
| Q2 FY2020 | Jun 30, 2020 | -41.4% | +188.0 |
| Q1 FY2020 | Mar 31, 2020 | -29.1% | +95.9 |
| Q4 FY2019 | Dec 31, 2019 | -7.7% | +249.7 |
| Q3 FY2019 | Sep 30, 2019 | -19.3% | +74.3 |
| Q2 FY2019 | Jun 30, 2019 | -229.4% | −210.2 |
| Q1 FY2019 | Mar 31, 2019 | -125.0% | +70.9 |
| Q4 FY2018 | Dec 31, 2018 | -257.4% | −293.1 |
| Q3 FY2018 | Sep 30, 2018 | -93.5% | +38.5 |
| Q2 FY2018 | Jun 30, 2018 | -19.2% | +406.7 |
| Q1 FY2018 | Mar 31, 2018 | -196.0% | +400.2 |
| Q4 FY2017 | Dec 31, 2017 | 35.7% | +270.7 |
| Q3 FY2017 | Sep 30, 2017 | -132.0% | +655.0 |
| Q2 FY2017 | Jun 30, 2017 | -425.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -596.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -234.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -787.0% | – |
See a number that looks wrong?